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Artemisinin resistance containment in Myanmar was initi-
ated in 2011 after artemisinin-resistant Plasmodium falci-
parum malaria was reported. Molecular evidence suggests 
that asymptomatic malaria infections harboring drug resis-
tance genes are present among residents of the Myanmar 
artemisinin resistance containment zone. This evidence 
supports efforts to eliminate these hidden infections.
The global burden of malaria has been decreasing in recent years as a result of high levels of control of 
the spread of infection, and the ultimate goal of malaria 
elimination by 2030 in all Greater Mekong Subregion 
countries in Southeast Asia seems attainable (1). However, 
artemisinin-resistant Plasmodium falciparum malaria has 
been reported in Cambodia, Thailand, Myanmar, Laos, and 
Vietnam (2). Chloroquine-resistant P. vivax malaria has 
also been confirmed in 10 countries, including Myanmar 
(3), and mutations in the mefloquine-resistance molecu-
lar marker (pvmdr1 mutation) and sulfadoxine/pyrimeth-
amine-resistance markers (pvdhps, pvdhfr mutations) have 
been reported in Myanmar (4).
A containment program for artemisinin-resistant ma-
laria was initiated in 2011 according to the Global Plan for 
Artemisinin Resistance Containment. Areas where artemis-
inin resistance was documented were ranked as Tier I under 
the protocol, whereas areas where resistance was suspected 
were ranked as Tier II. After Myanmar artemisinin resis-
tance containment (MARC) was initiated, malaria morbid-
ity and mortality rates decreased dramatically, especially 
in MARC Tier I areas (5). However, there are no reports 
on the prevalence of asymptomatic infections, which may 
represent a reservoir of local malaria transmission. In this 
study, we aimed to determine the prevalence of asymptom-
atic malaria infection and to analyze drug-resistance mark-
ers in asymptomatic P. falciparum and P. vivax infections.
The Study
As of 2014, the Tier I area of artemisinin resistance in 
Myanmar was composed of 52 townships; the remain-
ing regions were designated as Tier II. In January 2015, 
we conducted a cross-sectional study of one of the Tier 
I areas of the MARC, Shwegyin Township (22°20′0″N, 
95°56′0″E) (Figure; online Technical Appendix, https://
wwwnc.cdc.gov/EID/article/23/3/16-1363-Techapp1.pdf).
Rapid diagnostic tests (RDTs) (HRP2 and P. vivax–
specific pLDH-based RDT, SDFK80; Standard Diagnos-
tics, Gyeonggi-do, South Korea), microscopy, and PCR 
were used to screen for asymptomatic malaria infection 
(online Technical Appendix). We examined 1,182 local 
residents, with a male:female ratio of 4:5 and a median age 
of 30 years (interquartile range 18–45 years). Among these 
residents, 549 (46.4%) had a history of malaria infection 
within the past 5 years. No clinical cases of malaria infec-
tion were detected during the survey period. Although we 
found no RDT-positive cases of malaria infection, we de-
tected 2 P. vivax infections by microscopy, with parasite 
densities of 580 and 1,200 parasites/µL.
When we performed molecular detection for the 4 
common malaria species (online Technical Appendix), the 
overall rate of asymptomatic malaria infection was 2.4% 
(28/1,180) and included 4 P. falciparum, 22 P. vivax, and 2 
P. malariae infections. Although the overall prevalence of 
asymptomatic infection in these areas was not high, it was 
similar to that observed in the Thailand–Myanmar border 
area during 2013–2014 (6).
In this study, RDT and microscopy missed almost all 
the asymptomatic infections detected by PCR, indicating 
that only the molecular method is suitable for the detec-
tion of asymptomatic infections. Moreover, the asymp-
tomatic cases were broadly distributed geographically 
throughout the study area. Most of the infections were 
in male patients (19/28, 67.8%) and in the working-age 
group. Neither sex nor occupation was identified as an as-
sociated factor for asymptomatic infection (online Tech-
nical Appendix Table 2).
The established artemisinin-resistance marker K13 
(kelch 13 gene) and the associated markers pfarps10 (P. 
falciparum apicoplast ribosomal protein S10), pffd (P. fal-
ciparum ferredoxin), and pfmdr2 (P. falciparum multidrug-
resistance protein 2) were analyzed in all asymptomatic 
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P. falciparum cases. Nonsynonymous mutations in the 
propeller region of K13 were found to be associated with 
artemisinin resistance and associated delayed clearance of 
the parasite beyond 72 hours after treatment with artemis-
inin-based combination therapy (7). A previous study in the 
same region of patients with uncomplicated P. falciparum 
malaria indicated that 25.3% carried mutant K13 alleles 
(8). Markers that showed the underlying genetic back-
ground predisposing to the K13 mutant were also reported, 
including pfarps10, pffd, pfmdr2, and pfcrt. Specific single 
nucleotide polymorphisms of these genes, such as V127M 
of pfarps10, D193Y of pffd, and T484I of pfmdr2, were 
found at a similar prevalence as K13 mutations (9).
Among the 4 asymptomatic P. falciparum infections, 
2 isolates showed K13 mutations (C580Y in 1 isolate and 
P574L in the other). C580Y is a well-known validated mu-
tation, and P574L is a candidate marker for artemisinin re-
sistance. Both mutations were reported only in locations 
in Southeast Asia where artemisinin resistance has been 
identified (2). Moreover, we observed the pfarps10 muta-
tion (V127M) in 2 of the cases, the pffd mutation (D195Y) 
in 3 cases, and the pfmdr2 (T484I) mutation in all 4 isolates 
(Table; online Technical Appendix Table 3). This molecu-
lar evidence suggests the presence of artemisinin resistance 
in asymptomatic isolates and calls for action toward elimi-
nating this parasite reservoir.
Similarly, we analyzed all available drug-resistance 
molecular markers in P. vivax (10), such as pvcrt (P. vivax 
chloroquine-resistance transporter), pvdhps (P. vivax di-
hydropteroate synthase), pvdhfr (P. vivax dihydrofolate 
reductase), and pvmdr1 (P. vivax multidrug-resistance pro-
tein 1), in all P. vivax infections. We conducted analysis 
by using nested PCR, followed by gene sequencing (online 
Technical Appendix).
Among the 22 asymptomatic P. vivax infections, we 
were unable to amplify pvcrt-o, pvdhfr, and pvmdr1 in 
1 isolate and pvdhps in 2 isolates. A high mutation rate 
was observed in known drug-resistance markers such 
as pvcrt-o K10 AAG insert (66.6%, 14/21), pvdhps 
(100.0%, 20/20), pvdhfr (100.0%, 21/21), and pvmdr1 
(100.0%, 21/21) (Table). Asymptomatic isolates in this 
study showed a higher mutation rate of the pvcrt-o AAG 
insert than those studied in neighboring countries such as 
Thailand (11), India (12), and China (10). In the pvmdr1 
gene, both Y976F and F1076L mutations were observed 
in 23.8% of cases and F1076L in 19.0% of cases; these 
rates were higher than those for China (10) and India (12) 
but lower than those for Thailand (13,14). Although an-
tifolates are not the recommended antimalarial drugs for 
treatment of P. vivax, pvdhfr and pvdhps mutation rates 
were noticeable. This finding indicates that drug pressure 
in P. vivax malaria contributing to drug resistance also 
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Figure. The study site, Shwegyin 
Township, Myanmar, where 
molecular evidence of drug 
resistance in asymptomatic 
malaria infections was obtained. 
As of 2014, Myanmar artemisinin 
resistance containment areas  
were divided into Tier I (52 
townships) and Tier II (all 
remaining townships).
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needs to be considered in addition to emphasizing the 
artemisinin-resistant P. falciparum malaria.
One limitation of this study is the exclusive focus on 
the local residents in the MARC area, where all available 
control and prevention measures had already been imple-
mented. Unlike the mobile and migrant population, local 
residents have not been a top priority for the artemisinin re-
sistance containment program, leading to a niche of hidden 
infection. Moreover, blood pooling before DNA extraction 
was used in this study for molecular detection of malaria 
infection. Although this method is not ultrasensitive, it has 
a higher sensitivity than RDT and microscopy. The hidden 
asymptomatic infections and associated molecular markers 
for drug resistance among the asymptomatic cases detected 
in this study represent a threat to containment and elimina-
tion efforts with regard to drug-resistant parasites.
Conclusions
All countries in the Greater Mekong Subregion have set an 
ultimate goal of eliminating malaria by 2030. One of the 
main challenges to achieving this goal is hidden asymp-
tomatic infection, which maintains a reservoir for local 
transmission of malaria (15). Critically, these asymptom-
atic infections may carry drug-resistance genes, including 
genes for artemisinin resistance. Our results indicated that 
drug-resistant malaria parasites may be spreading, even in 
the containment areas or (pre-)elimination areas; this issue 
should, therefore, be addressed at a policy level. Detection 
and elimination of asymptomatic infections are of vital im-
portance. Our evidence highlights the need for a strategy 
for eliminating drug-resistant malaria in asymptomatic in-
fections in the containment areas.
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Table. Plasmodium falciparum and P. vivax drug-resistance molecular markers in asymptomatic infections, Myanmar, 2015 
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and Sal-1 (P. vivax) reference sequences from http://www.plasmodb.org. 
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